Allscripts Sells Precision Medicine Subsidiary 2bPrecise

Aug. 27, 2021
Allscripts Healthcare Solutions has sold its precision medicine subsidiary 2bPrecise to AccessDX Holdings, an advanced laboratory diagnostic solutions. The platform synthesizes genetic/genomic data from molecular labs and clinical data from EHRs.

Allscripts Healthcare Solutions has sold its precision medicine subsidiary 2bPrecise to AccessDX Holdings, a provider of advanced laboratory diagnostic solutions, for an undisclosed amount.

The 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. It brings the resulting precision medicine insights into a physician’s EHR workflow.

Healthcare Innovation recently spoke with a physician leader with Michigan-based Genesys PHO (physician hospital organization) about their work with a solution from 2bPrecise for introducing pharmacogenomics into family medicine practice.

2bPrecise said its platform enables organizations to amplify their precision medicine strategies by delivering point-of-care insights so providers can identify patients at risk for heritable conditions, arrive at precise diagnoses more quickly and initiate optimal therapies more quickly.

2bPrecise will join Houston-based AccessDX’s portfolio of diagnostics, software and services, including the MedTek21 software platform which facilitates diagnostic-based clinical decision support, compliance and program analytics for thousands of care organizations, patient groups and providers. AccessDX said the combination with 2bPrecise would ensure meaningful insights will be accessible within the clinical workflow of any EHR, while helping organizations streamline virtually all aspects of establishing and supporting precision medicine programs.

AccessDX describes MedTek21 as a real-time population health and medication risk management platform. It works alongside EHRs to continuously monitor, proactively identify, and help remediate potential medication risks.

“AccessDX is a genuine leader in genomic information management. Our collective capabilities will serve as a force multiple for the practical utilization of precision medicine,” said Assaf Halevy, founder and CEO of 2bPrecise, in a statement. “With a unified mission to drive dimensional change in healthcare, the combined talents and energy of 2bPrecise and AccessDX will compound acceleration in delivering on our vision of intelligent, personalized care for the good of healthcare organizations and the patients they serve.”

Sponsored Recommendations

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

TEST: Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

From Strategy to Action: The Power of Enterprise Value-Based Care

Ever wonder why your meticulously planned value-based care model hasn't moved beyond the concept stage? You're not alone! Transition from theory to practice with enterprise value...